Infectious diseases such as malaria, dengue, and tuberculosis are considered to pose as great a challenge to global health as new or emerging pathogens, according to a major international study ...
Dans le cadre du lot de travail 2 du projet ODIN, une campagne d'échantillonnage des eaux usées et de l'environnement a été lancée en janvier 2025 et s'est poursuivie ...
In ODIN Work Package 2, the wastewater and environmental sampling campaign ran from January to September 2025 across Tanzania, Burkina Faso, and the Democratic Republic of the Congo (DRC). ...
Public health professionals from across Southeast Asia have delivered their first independently-run simulation exercise training – marking a significant step towards self-sufficient regional response capabilities. In November 2025, newly trained ...
Adriana Krolicka Introduction: Adriana Krolicka est chercheuse senior au Centre norvégien de recherche (NORCE) et possède plus de 15 ans d'expérience en écologie moléculaire et en microbiologie environnementale. Ses travaux ...
It aims to guide researchers, funders, and policymakers in aligning ongoing and future studies with the most pressing policy needs. The agenda also aims to strengthen coordination and ensure that new evidence directly informs national and regional vaccine readiness decisions. Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
On Sept 8, 2025, West African Ministers of Health pledged their joint commitment to advance development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant regional health security threat posed by the disease Read more
Developed from a systematic review of peer-reviewed studies, this platform allows users to explore findings by country, vaccine, drug, disease, surveillance method, participant group, and study year. The tool supports vaccine and drug developers, pharmacovigilance programs, and public health stakeholders ... Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
SPEAC’s Special Populations team, in collaboration with Instituto de Efectividad Clínica y Sanitaria (IECS) and Tulane University, has launched an LSR and meta-analysis tool focused on the safety, effectiveness, and immunogenicity of mpox vaccines Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
